Hepatitis B Virus News and Research

RSS

Large-scale clinical trial begins to study liver transplantation between people with HIV

The first large-scale clinical trial to study liver transplantation between people with HIV has begun at clinical centers across the United States. The HOPE in Action Multicenter Liver Study will determine the safety of this practice by evaluating liver recipients for potential transplant-related and HIV-related complications following surgery.

15 Feb 2019

Study can have implications in the vaccination policies against Hepatitis A

Researchers of the University of Barcelona have analyzed, with massive sequencing techniques for the first time, the evolution of the Hepatitis A virus with samples from patients.

11 Feb 2019

Standard method for ranking liver transplant waitlists may not prioritize the sickest candidates

A new study has uncovered that the standard method for ranking patients on the waitlist for lifesaving liver transplantation may not prioritize some of the sickest candidates for the top of the list.

25 Jan 2019

Study reveals how Hepatitis C infection varies by state and region

Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

24 Dec 2018

Researchers synthesize new compound that inhibits replication of hepatitis C virus

A new compound that inhibits the replication of hepatitis C virus in several stages of its lifecycle - and is also capable of acting on bacteria, fungi and cancer cells - has been synthesized by researchers at São Paulo State University in Brazil.

19 Dec 2018

Viral hepatitis: Liver failure caused by defects in the vascular system

In severe cases, a viral hepatitis infection can result in liver failure. A team from the Technical University of Munich has now discovered how this occurs: by immune cells attacking cells in the vascular system, which disrupts the organ's blood and nutrient supply.

19 Dec 2018

Study finds new strains of hepatitis C virus in sub-Saharan Africa

The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

17 Dec 2018

Study finds drug targets for Ebola, Dengue, and Zika viruses

No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes and UC San Francisco may finally change that. Scientists identified key ways the three viruses hijack the body's cells, and they found at least one potential drug that can disrupt this process in human cells.

13 Dec 2018

RUDN medics first to gather scattered data on hepatitis morbidity in Somalia

Viral hepatitis means liver inflammation caused by viruses and is among top-10 mortality factors in the world. It is passed with contaminated food and water, through contact with infected blood, via common use of household appliances such as manicure or shaving sets.

13 Dec 2018

Genetic relic of the 'Black Death' may provide clues for treating fatal liver scarring

A gene mutation that is believed to have safeguarded some people in 14th century Europe from the bubonic plague today may be protecting HIV patients co-infected with hepatitis C from potentially fatal liver scarring, says a University of Cincinnati College of Medicine physician-scientist.

3 Dec 2018

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

29 Nov 2018

FIND explores new diagnostic assays for confirmatory HCV diagnosis in community settings

The Foundation for Innovative New Diagnostics today announced awards to support the development, manufacture and feasibility testing of two prototype hepatitis C virus core antigen immunoassays for confirmatory HCV diagnosis at the point of care.

16 Nov 2018

NIH researchers shed light on causes of HBV-associated acute liver failure

National Institutes of Health scientists and their collaborators found that hepatitis B virus-associated acute liver failure--a rare condition that can turn fatal within days without liver transplantation--results from an uncommon encounter between a highly mutated HBV variant and an unusual immune response in the patient's liver that is mainly sustained by antibody-producing B cells.

14 Nov 2018

Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma

Hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma (HCC) and was estimated to be responsible for 745,000 deaths in 2012.

13 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Research reveals high stability of hepatitis B viruses

At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

30 Oct 2018

Researchers identify new potential target to inhibit progression of liver disease

Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease.

26 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

One-time universal screening recommended to tackle increase in hepatitis C

Physicians are encountering a growing number of younger patients who are testing positive for hepatitis C virus fueled largely by the opioid crisis impacting communities around the country.

17 Oct 2018

Antimicrobial signaling molecule has lower activity against hepatitis C virus in most humans

An antimicrobial signaling molecule called IFNλ4 has lower activity against the hepatitis C virus in the vast majority of humans compared with chimpanzees and African hunter-gatherer Pygmies, according to a study published October 11 in the open-access journal PLOS Pathogens by John McLauchlan’s research team at the MRC-University of Glasgow Centre for Virus Research in the UK, and colleagues.

12 Oct 2018